01873 維亞生物
按盘价 
1.760 +0.170 (+10.692%) 盈利能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 资产回报率 (%) | 2.307% | -1.511% | -6.620% | 3.550% | -7.697% |
| 股东资金回报率 (%) | 4.467% | -3.382% | -15.958% | 8.542% | -15.275% |
| 资本运用回报率 (%) | 2.824% | -1.963% | -10.069% | 4.040% | -5.215% |
边际利润分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 毛利率 (%) | 34.601% | 34.257% | 34.278% | 30.939% | 43.742% |
| 未计利息、税项、折旧及摊销前利润率 (%) | 27.183% | 13.994% | -4.950% | 31.134% | -34.671% |
| 税前边际利润率 (%) | 14.885% | -2.596% | -19.296% | 16.525% | -51.109% |
| 纯利率 (%) | 8.421% | -5.387% | -22.208% | 13.666% | -55.510% |
变现能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 流动比率 (X) | 1.666 X | 1.324 X | 0.725 X | 2.141 X | 4.556 X |
| 速动比率 (X) | 1.424 X | 1.155 X | 0.603 X | 1.891 X | 4.332 X |
财务杠杆分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 总负债 / 总资产比率 (%) | 45.874% | 50.497% | 54.491% | 51.355% | 53.927% |
| 总债项 / 总资产比率 (%) | 18.212% | 25.547% | 35.639% | 32.999% | 36.417% |
| 净债项 / 总资产比率 (%) | 4.857% | 11.636% | 27.072% | 23.043% | 8.107% |
| 总债项 / 股东资金比率 (%) | 33.770% | 51.607% | 88.813% | 77.068% | 90.311% |
| 长期债项 / 股东资金比率 (%) | 19.240% | 25.781% | 28.528% | 70.137% | 85.233% |
| 净债项 / 股东资金比率 (%) | 9.007% | 23.506% | 67.465% | 53.816% | 20.105% |
| 净现金 / (债项) ($) | (3.42亿) | (8.67亿) | (21.44亿) | (18.54亿) | (6.61亿) |
| 每股净现金 / (债项) ($) | (0.161) | (0.401) | (1.108) | (0.958) | (0.345) |
| 总债项 / 资本运用比率 (%) | 21.676% | 32.172% | 53.788% | 37.295% | 40.029% |
| 利息盈利率 (X) | 6.487 X | 0.683 X | N/A | 2.899 X | N/A |
营运效率分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 存货周转率日数 (日) | 74.785日 | 75.431日 | 65.085日 | 49.794日 | 80.651日 |
| 应收贸易帐周转率日数 (日) | 76.051日 | 72.250日 | 67.158日 | 65.071日 | 98.984日 |
| 应付贸易帐周转率日数 (日) | 50.994日 | 48.418日 | 46.566日 | 50.026日 | 79.408日 |
| 备注： | 实时报价更新时间为16/05/2025 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
